Skip Navigation


Carcinogenesis Advance Access originally published online on August 14, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow All Versions of this Article:
24/11/1749    most recent
bgg138v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Chang, P.-L.
Right arrow Articles by Hicks, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, P.-L.
Right arrow Articles by Hicks, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 24, No. 11, 1749-1758, November 2003
© 2003 Oxford University Press

CANCER BIOLOGY

Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells

Pi-Ling Chang1,2,4, Minhton Cao3 and Patricia Hicks1

1 Department of Nutrition Sciences and 2 Comprehensive Cancer Center, 311 Susan Mott Webb Nutrition Sciences Building, 1675 University Boulevard, University of Alabama at Birmingham, Birmingham, AL 35295-3360, USA and 3 School of Dentistry, University of Alabama at Birmingham, Birmingham, AL 35294-6630, USA

Osteopontin (OPN) is a secreted, adhesive glycoprotein. Elevated expression of OPN in malignant and benign tumors is postulated to play a role in tumorigenesis. To determine whether OPN induction is required for tumor promotion, we used the in vitro JB6 model known to correlate with tumor promotion in vivo. The skin tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) induces irreversible transformation of JB6 Cl41.5a cells. Concomitantly, TPA markedly stimulates early and persistent OPN expression and secretion for at least 4 days (the time required for these cells to begin to acquire the transformed phenotype) and increases cells' adhesion to OPN. Here, we demonstrated that dexamethasone, a synthetic analog of glucocorticoid, known to inhibit tumor promotion in vivo, not only suppressed TPA-induced OPN mRNA expression and inhibited tumorigenic transformation of JB6 Cl41.5a cells (as previously shown in JB6 Cl22 and Cl41 cells), but also that the addition of OPN partially restored dexamethasone suppression of TPA-induced cell transformation. Therefore, we tested the hypothesis that OPN induction is required for tumor promoter-induced transformation of JB6 cells by examining (i) whether the addition of OPN will induce transformation, (ii) whether antisense OPN expression will inhibit TPA-induced transformation and (iii) if the latter experiment showed inhibition of TPA-induced transformation whether the addition of OPN will rescue this effect. Results indicated that the addition of purified OPN induced a dose-dependent transformation of JB6 cells, as assessed by anchorage- independent growth assay and that this induction was suppressed by antibody to OPN. Furthermore, antisense OPN expressing JB6 clones suppressed TPA-induced OPN synthesis and secretion and inhibited TPA-induced anchorage-independent growth, which was partially rescued by the addition of OPN. In conclusion, OPN induction is required and can be sufficient to induce in vitro cellular transformation of a preneoplastic murine JB6 cell line.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
M. Yasuda, T. Nishizawa, H. Ohigashi, T. Tanaka, D.-X. Hou, N. H. Colburn, and A. Murakami
Linoleic acid metabolite suppresses skin inflammation and tumor promotion in mice: possible roles of programmed cell death 4 induction
Carcinogenesis, July 1, 2009; 30(7): 1209 - 1216.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
P.-L. Chang, L. Harkins, Y.-H. Hsieh, P. Hicks, K. Sappayatosok, S. Yodsanga, S. Swasdison, A. F. Chambers, C. A. Elmets, and K.-J. Ho
Osteopontin Expression in Normal Skin and Non-melanoma Skin Tumors
J. Histochem. Cytochem., January 1, 2008; 56(1): 57 - 66.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. P. Matthews, A. M. Birkholz, A. R. Baker, C. M. Perella, G. R. Beck Jr., M. R. Young, and N. H. Colburn
Dominant-Negative Activator Protein 1 (TAM67) Targets Cyclooxygenase-2 and Osteopontin under Conditions in which It Specifically Inhibits Tumorigenesis
Cancer Res., March 15, 2007; 67(6): 2430 - 2438.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y.-H. Hsieh, M. M. Juliana, P. H. Hicks, G. Feng, C. Elmets, L. Liaw, and P.-L. Chang
Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin.
Cancer Res., July 15, 2006; 66(14): 7119 - 7127.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. Feng, Y. Ohmori, and P.-L. Chang
Production of chemokine CXCL1/KC by okadaic acid through the nuclear factor-{kappa}B pathway
Carcinogenesis, January 1, 2006; 27(1): 43 - 52.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.